Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Becton, Dickinson and Company (BDXA) is a leading global medical technology company that specializes in the development and manufacturing of medical devices, instrument systems, and reagents. With a strong presence in North America and Europe, BDXA's product portfolio includes advanced drug delivery systems, diagnostic instruments, and surgical instruments, which are critical in healthcare settings. The company's competitive advantage lies in its extensive R&D capabilities and established relationships with healthcare providers.
BDXA generates revenue through the sale of medical devices and systems, which are often sold under long-term contracts to hospitals and healthcare providers. The company benefits from strong pricing power due to its reputation for quality and innovation, allowing it to maintain healthy gross margins. Additionally, BDXA's investment in R&D fosters product differentiation, enhancing its competitive position.
Changes in healthcare regulations affecting medical device approvals
Innovation and new product launches, particularly in drug delivery systems
Market share changes in key segments, especially in North America and Europe
Global healthcare spending trends, particularly in emerging markets
Technological disruption from emerging medical technologies and competitors
Regulatory changes that could impact product approval timelines
Increased competition from lower-cost manufacturers in emerging markets
Potential market share loss to innovative startups in the medical device sector
Moderate debt levels could pose risks if cash flows decline unexpectedly
Pension obligations may impact liquidity in the long term
moderate - BDXA's performance is somewhat linked to GDP growth and healthcare spending, which can fluctuate with economic cycles.
Interest rates affect BDXA primarily through financing costs for R&D and capital expenditures. Higher rates could compress margins if borrowing costs rise significantly, impacting valuation multiples.
minimal - BDXA is not heavily reliant on credit markets for its operations, given its strong cash flow generation.
growth - BDXA's focus on innovation and new product development appeals to growth-oriented investors.
low - BDXA has historically exhibited low volatility, with a beta of approximately 0.8.
